Medical Condition News

RSS

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

Novel way to fight UTIs: Research into Alzheimer's disease

Research into Alzheimer's disease seems an unlikely approach to yield a better way to fight urinary tract infections (UTIs), but that's what scientists at Washington University School of Medicine in St. Louis and elsewhere recently reported.

25 Nov 2009

Roche's xCELLigence RTCA DP Instrument with CIM-Plate 16 enables real-time monitoring of cell migration

Cell migration is an important process in the development of organisms, as well as during immune surveillance and wound healing. For cancer development, the potential of cells to migrate or to grow invasively is, in addition to proliferation, the most important disease-causing factor. The inhibition of cell migration is a key target of the new anti-inflammatory therapies.

25 Nov 2009

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Sucampo Pharma Europe, Ltd., and Sucampo Pharma Americas, Inc., subsidiaries of Sucampo Pharmaceuticals, Inc., today presented additional clinical data for lubiprostone (Amitiza®) at GASTRO 2009 UEGF/WCOG, the joint meeting of the United European Gastroenterology Federation (UEGF), the World Gastroenterology Organisation (WGO), the World Organisation of Digestive Endoscopy (OMED) and the British Society of Gastroenterology (BSG), in London.

25 Nov 2009

Johnson & Johnson Focused Funding grant for research on brain cell damage in PD

‏Dr. Sarit Larisch, Head of the Cell Death Research Laboratory and senior lecturer at the University of Haifa, has been awarded the prestigious Johnson & Johnson Focused Funding grant for her research exploring the cause of brain cell damage in Parkinson's disease.

25 Nov 2009

Given Imaging's PillCam SB wireless capsule endoscopy effective in treating GI patients

Given Imaging Ltd., the global leader in patient-friendly GI diagnostic and monitoring solutions, today announced that three new studies demonstrate that PillCam® SB endoscopy has a clear impact on how physicians manage GI patients, including those patients suspected of having Crohn's disease. The studies were presented at the Gastro 2009 conference taking place in London from November 21 to 25.

25 Nov 2009

UGR researchers provide early diagnosis of ARMD and keratitis

Researchers from the UGR have provided an early diagnosis of certain ocular diseases that are very common today, such as age-related macular degeneration and keratitis, by applying an existing optical technique that, nevertheless, had never before been used for this purpose.

25 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Multiple Sclerosis Society of Canada to invite research operating grant proposals related to CCSVI and MS

The Multiple Sclerosis Society of Canada announced it will request research operating grants related to chronic cerebrospinal venous insufficiency (CCSVI) and MS.

25 Nov 2009

'Suicide gene E' reduces potent drug dosage in cancer patients

Researchers at the University of Granada have found a suicide gene, called 'gene E', which leads to the death of tumour cells derived from breast, lung and colon cancer, and prevents their growth. The importance of this new gene is that its use to fight cancer can reduce the potent drugs that are currently used, so that could mean more effective treatment for cancer.

25 Nov 2009

Plasma albumin levels and cardiovascular disease risk factors influenced by common genetic components

Two indicators of liver function, glutamyl transferase (GGT) and albumin (ALB) have been implicated in the pathogenesis of atherosclerosis. It is known that the variation in the plasma level of these liver related proteins is genetically influenced.

25 Nov 2009

CVS/pharmacy and Warner Home Video team up to raise critical funds for cystic fibrosis

The Cystic Fibrosis Foundation announced today that CVS/pharmacy and Warner Home Video will partner with the Foundation this holiday season to raise critical funds for cystic fibrosis through the sale of classic family movies.

25 Nov 2009

New study reveals that dentists can help detect patients with cardiovascular disease

"Dentists are really proud of their profession and feel no need to encroach upon doctors' territory," says senior dental officer and professor Mats Jontell at the Sahlgrenska Academy. "However, we wanted to find out if we as a profession could identify patients at risk of cardiovascular disease."

25 Nov 2009

Study may pave way for potential drug targets in lung cancer treatment

Researchers from Boston University School of Medicine (BUSM) and the Boston University Biomedical Engineering Department have identified a number of proteins whose activation allows them to distinguish between cancer and normal cells with almost 97 percent accuracy.

25 Nov 2009

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

ChemoCentryx, Inc., announced today that Phase II/III clinical data from the Company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN(TM) (CCX282-B) in patients with moderate-to-severe Crohn's disease demonstrated clinical efficacy with a favorable safety and tolerability profile. The

25 Nov 2009

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that presentations of clinical data for three product candidates employing its Targeted Antibody Payload (TAP) technology will be made at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition to be held in New Orleans, LA, on December 5-8, 2009.

25 Nov 2009

Exercise and education program reduces disability and improves physical function after back surgery

Patients who have undergone a single-level lumbar microdiskectomy for lumbar disk herniation experienced significant improvement in physical function following an intensive, progressive physical therapist guided exercise and education program, according to a research report published in the November issue of Physical Therapy (PTJ), the scientific journal of the American Physical Therapy Association (APTA).

25 Nov 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

New Brunswick's colorectal cancer screening program lauded by CCAC

The Colorectal Cancer Association of Canada (CCAC) applauds the decision of the New Brunswick's Minister of Health Mary Schryer to implement a province wide colorectal cancer screening program and to provide funding for Avastin (bevacizumab) for patients with metastatic colorectal cancer.

25 Nov 2009

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc., today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York.

25 Nov 2009

Medical Condition News

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Novel way to fight UTIs: Research into Alzheimer's disease

Roche's xCELLigence RTCA DP Instrument with CIM-Plate 16 enables real-time monitoring of cell migration

Additional data on lubiprostone presented at the GASTRO 2009 UEGF/WCOG meeting

Johnson & Johnson Focused Funding grant for research on brain cell damage in PD

Given Imaging's PillCam SB wireless capsule endoscopy effective in treating GI patients

UGR researchers provide early diagnosis of ARMD and keratitis

Human Genome Sciences submits BLA for ZALBIN

Multiple Sclerosis Society of Canada to invite research operating grant proposals related to CCSVI and MS

'Suicide gene E' reduces potent drug dosage in cancer patients

Plasma albumin levels and cardiovascular disease risk factors influenced by common genetic components

CVS/pharmacy and Warner Home Video team up to raise critical funds for cystic fibrosis

New study reveals that dentists can help detect patients with cardiovascular disease

Study may pave way for potential drug targets in lung cancer treatment

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Clinical data on ImmunoGen's TAP compounds to be presented at the 51st ASH meeting

Exercise and education program reduces disability and improves physical function after back surgery

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

New Brunswick's colorectal cancer screening program lauded by CCAC

Myasthenia Gravis Alliance receives Global Pharmaceuticals grant to further research and awareness

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News